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Objectives: The ability of current immunoassays to accurately measure equimolar amounts of 25(OH)D2 and
25(OH)D3 has been recently questioned. This study determined serum 25(OH)D2, 25(OH)D3 and total serum
25(OH)D concentrations in healthy vitamin D2-supplemented subjects by isotope dilution liquid chromatography
mass spectrometry (ID-LC-MS/MS); and, evaluated the ability of the Siemens, DiaSorin, Roche, and Abbott Vitamin
D Total assays to monitor total serum 25(OH)D concentrations compared to an ID-LC-MS/MS method traceable to
the National Institute of Standards and Technology (NIST), and that has achieved certiﬁcation from the Centers
for Disease Control and Prevention (CDC) Vitamin D Standardization Certiﬁcation Program (VDSCP).
Design and methods: Twenty (20) healthy adults, with no history of prior vitamin D supplementation were
administered oral vitamin D2 (2400 IU/day for 6 months). Serum samples (140) from baseline and monthly
blood draws were tested.
Results: After one month, the mean serum 25(OH)D2 concentrations rose from 0.8 to 43.6 nmol/L, whereas
25(OH)D3 concentrations declined from 84.0 to 63.4 nmol/L; total serum 25(OH)D concentrations rose from 86.6
to 107.0 nmol/L. The overall mean bias to ID-LC-MS/MS was −7.1% for the Siemens ADVIA Centaur assay,
−15.3% for the DiaSorin LIAISON assay; −8.4% for the Roche ELECSYS assay and −16.3% for the Abbott
ARCHITECT assay. Correlation coefﬁcients (r) were 0.94, 0.79, 0.74, and 0.73; the mean bias for baseline [25(OH)
D3-containing] versus six-month [25(OH)D2- and 25(OH)D3-containing] samples was −13.4% and −5.7%;
−3.5% and 20.3%, 9.6% and−12.1%, and 0.2% and−17.8%, respectively.
Conclusions: The bias results obtained for the Siemens ADVIA Centaur assay and Roche ELECSYS assay were
slightly lower than those for the DiaSorin LIAISON assay and the Abbott ARCHITECT assay, but all 25(OH)D assays
demonstrated acceptable performance.
© 2015 Siemens Healthcare Diagnostics Inc. The Canadian Society of Clinical Chemists. Published by Elsevier Inc.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Vitamin D deﬁciency, as determined by serum concentrations of
25(OH)D [ie., the sum of 25(OH)D3 and 25(OH)D2] is known to compro-
mise musculoskeletal health [1,2]. This knowledge has spurred an
increase in demand for 25(OH)D testing which has ledmany laboratories
to replace radioactive methods with fully automated immunoassays. The
term “Vitamin D” represents a family of related secosteroids whose
parent compound exists in two forms—one made by skin exposed to
UVB sun rays (cholecaliferol, vitamin D3) and the other made by plants,
fungi, and ﬁsh (ergocalciferol, vitamin D2) [1,3]. Both forms of vitamin
D undergo identical hydroxylations to yield 25-hydroxyvitamin D
[25(OH)D] in the liver and 1,25-dihydroxyvitamin D [1,25(OH)2D] in
the kidney [1]. Although 1,25(OH)2D is the biologically active metabo-
lite of vitamin D, 25(OH)D generally represents the best marker ofeman),
siemens.com (R. Spears),
@siemens.com (P. Sibley).
The Canadian Society of Clinical Chvitamin D nutritional status that better reﬂects calcium absorption [4]
and disease states that respond to supplementation [1,2,5–7]. Nutritional
supplements may contain either vitamin D3 or vitamin D2 forms [2].
Depending on the dosage regimen and study population, supplementa-
tion with either formmay augment total serum 25(OH)D concentrations
[8–16], and correlate with efﬁcacy [17–19]. Several reports have demon-
strated that vitamin D2 is less potent than vitamin D3 in raising serum
25(OH)D concentrations; [8,10,20–26] whereas, other reports demon-
strate equipotency [9,13].
How vitamin D2 supplementation affects endogenous 25(OH)D2,
25(OH)D3 and total 25(OH)D has been the subject of several studies
in recent years. Some reports demonstrate a compensatory decline in
25(OH)D3 serum concentrations concomitant with an increase in
25(OH)D2 serum concentrations compared to baseline [8,10,23,27].
Peak concentrations of serum 25(OH)D after dosing were found to be
variable—greater [8], lower [23], or not changed [13,27]. The variable
results likely reﬂect differences in study design that include dosing
regimen, study population, season, and latitude. Endogenous 25(OH)D2
concentrations are generally very low (less than ﬁve percent of totalemists. Published by Elsevier Inc. This is an open access article under the CC BY license
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ratio may change substantially after vitamin D2 supplementation [8,10,
11,13,23,27]. Thus, current guidelines for the measurement of total
serum 25(OH)D concentrations stipulate that assays must recognize
serum 25(OH)D3 and 25(OH)D2 in equimolar amounts in order to
avoid underrepresentation and misdiagnosis of total serum 25(OH)D
concentrations [28].
In the past, variability was reported in the ability of automated immu-
noassays to accuratelymeasure serum25(OH)D2 concentrations [29–32].
The afﬁnity for 25(OH)D2 and other vitamin D metabolites was found
to differ between assays, which—depending on the assay—reportedly
overestimated [29,30,32], or underestimated 25(OH)D2 concentrations
[29,30,32,33]. Assays reported to overestimate 25(OH)D2 concentrations
included Siemens ADVIA Centaur® Vitamin D Total (Siemens, Tarrytown,
NY, USA) [29,30,32]. Assays reported to underestimate 25(OH)D2 concen-
trations were Abbott ARCHITECT 25-OH Vitamin D (Abbott, Deerﬁeld, IL,
USA) [29,32], and Roche ELECSYS Vitamin D Total (Roche Diagnostics,
Mannheim, Germany) assays [29]. The DiaSorin LIAISON 25 OH Vitamin
D TOTAL assay (DiaSorin, Stillwater, MN, USA) has been reported to
over-recover [32] and under-recover [29,30,33] 25(OH)D2 concentra-
tions, depending on the study.
The goal of this study was to evaluate the ability of four current Vita-
minD Total immunoassays (from Siemens, DiaSorin, Abbott, and Roche)
by comparison with a VDSCP-certiﬁed ID-LC-MS/MS method traceable
to NIST to accurately measure and monitor serum total 25(OH)D
concentrations in serum samples from subjects receiving vitamin
D2 supplementation.
2. Materials and methods
2.1. Sample population and study design
One hundred and forty seven (147) archived and non-identiﬁable
clinical serum samples from 23 apparently healthy adult donors were
purchased from a commercial vendor (Research Sample Bank, Inc.,
Delay Beach, FL, USA). Written informed consent was obtained from
all participants. One subject withdrew from the study before, and two
others withdrew from the study after the ﬁrst monthly blood draw.
Thus, results are presented for those 20 subjects that completed the
study (total of 140 samples). The Roche ELECSYS Vitamin D Total
assay and Abbott ARCHITECT 25-OH Vitamin D assay, each measured
25(OH)D concentrations in 139 total samples due to loss of one sample
after the ﬁrst month. ID-LC-MS/MS results at baseline conﬁrmed virtu-
ally undetectable serum concentrations of 25(OH)D2. The average age
for the 20 remaining subjects at the end of the study was 41 years
(range 22–72 years). Seven subjects were females and 13 subjects
were males. All subjects initiated the study between April 16, 2013
and April 17, 2013 and ended the study between October 15, 2013
and November 27, 2013. Bloodwas drawn from 23 healthy donors—not
previously vitamin D supplemented—at baseline and at approximately
1, 2, 3, 4, 5, and 6 months after supplementation with ergocalciferol, vi-
tamin D2–2400 IU daily by oral route (Deva VeganVitamins Vegan vita-
min D2, DEVA Nutrition LLC, info@devanutrition.com). After collection,
blood was placed at 4 °C, centrifuged, and serum aliquots were pre-
pared. Serum samples were stored at−20 °C for less than nine months
until theywere sent to Siemens Healthcare Diagnostics Inc. (Tarrytown,
NY, USA). At Siemens Healthcare Diagnostics Inc. samples were sent to
LabCorp (Cranford, NJ, USA) where total serum 25(OH)D concentra-
tions were measured using the DiaSorin LIAISON 25 OH Vitamin D
TOTAL assay; and, 25(OH)D-total, 25(OH)D3, and 25(OH)D2were sepa-
rated andmeasured by the Esoterix ID-LC-MS/MSmethod (test number
500116). Total serum 25(OH)D concentrations were measured using
the Siemens ADVIA Centaur Vitamin D Total assay, Roche ELECSYS Vita-
min D Total assay, and Abbott ARCHITECT 25-OHVitamin D assay at Sie-
mens Healthcare Diagnostics Inc. ADVIA Centaur is a registered
trademark of Siemens Healthcare Diagnostics Inc. All other trademarksand brands are the property of their respective owners. The ID-LC-MS/
MS 25(OH)D2, 25(OH)D3 and total 25(OH)D values are expressed as
nmol/L. Concentrations in nmol/L for 25(OH)D2, 25(OH)D3 and total
25(OH)D for each assay were calculated using the ID-LC-MS/MS
25(OH)D2/25(OH)D3 ratio.
2.2. Method comparison and traceability
Three of the assays evaluated in this study are competitive chemilu-
minescent immunoassays—Siemens ADVIA Centaur assay [34], DiaSorin
LIAISON assay [35], and Abbott ARCHITECT assay [36]. The Roche
ELECSYS Vitamin D Total assay is an electrochemiluminescence protein
assay that involves capture of 25(OH)D by vitamin D binding protein
[37]. Traceability of the assays can be found in the manufacturer's
Instructions for Use as to the performance of the assays.
2.2.1. ADVIA Centaur assay
[34] The assay is traceable to the Ghent University 25(OH)vitamin D
ReferenceMeasurement Procedure (RMP) and has also achieved certiﬁ-
cation from the CDC-VDSCP [28,38–40]. When this study was per-
formed the ADVIA Centaur Vitamin D Total assay was the only assay
of the ones tested that was CDC-VDSCP certiﬁed. The standardized
assay is reported to demonstrate equimolar cross-reactivity with
25(OH)D2 (104.5%) and 25(OH)D3 (100.7%), minimal cross-reactivity
with 3-epimer of 25(OH)D3 (3-epi-25(OH)D3) (1.1%), and a broad assay
range of 10.5–375 nmol/L (4.2–150.0 ng/mL). The Limit of Quantitation
(LoQ) of the assay is 10.5 nmol/L (4.2 ng/mL). Precision analysis involved
assaying six samples twice a day in replicates of 2, over 20 days (n = 80
replicates per sample) according to the Clinical and Laboratory Standards
Institute (CLSI) protocol EP5-A2; [41] the run-to-run CVs were in the
range of 4.2% and 11.9%. All samples were run in singlicate on both the
ID-LC-MS/MS and a single ADVIA Centaur system.
2.2.2. Abbott ARCHITECT assay
[36] The assay is reported to demonstrate 105% cross-reactivity with
25(OH)D3, 82% cross-reactivity with 25(OH)D2, 12.6% cross-reactivity
with 1,25(OH)2D3, 112% cross-reactivity with 24,25(OH)2D3, minimal
cross-reactivity with 3-epi-25(OH)D3 (2.7%), and a measuring interval
of 32.5–240.0 nmol/L (13.1–96.2 ng/mL). The LoQ of the assay is
20 nmol/L (8 ng/mL). Precision studies, as reported in the assay Instruc-
tions for Use, used six samples—3VitaminD Controls and 3 serumbased
samples, using two lots of reagents, in replicates of two, twice per day
for 20 days (n= 80 replicates per sample), according to the CLSI proto-
col EP05-A2 [41]. The reported total between run CVs for the vitamin D
assay control samples ranged from 2.7 to 4.6% (190.8–48.8 nmol/L,
76.3–19.5 ng/mL); and for the serum samples from 2.6 to 4.0%
(178.3–57.5 nmol/L, 71.3–23.0 ng/mL).
2.2.3. Roche ELECSYS assay
[37] The assay reportedly demonstrates 100% cross-reactivity
with 25(OH)D3, improved 92% cross-reactivity with 25(OH)D2,
91% cross-reactivity with 3-epi-25(OH)D3, 149% cross reactivity
with 24,25(OH)D3; and a measuring range of 12.5–150.0 nmol/L
(5.0–60 ng/mL). The LoQ of the assay is 12.5 nmol/L (5.0 ng/mL). Pre-
cision, as reported in the assay Instructions for Use (IFU), was determined
by 2 runs per day in duplicate and each for 21 days (n=84 replicates per
sample) according to a CLSI modiﬁed protocol EP05-A2; [41] the run-to-
run CVs ranged from 1.6 to 7.2% (132.0–15.5 nmol/L, 52.6–6.2 ng/mL).
2.2.4. DiaSorin LIAISON assay
[35] The assay is reported to demonstrate equimolar cross-reactivity
with 25(OH)D2 (104%) and 25(OH)D3 (100%), cross-reactivity with 3-
epi-25(OH)D3 of b1.0%, and a measuring range of 10.0–375.0 nmol/L
(4.0–150.0 ng/mL). The LoQ of the assay is 10.0 nmol/L (4.0 ng/mL).
Precision, as reported in the assay Instructions for Use, was determined
by assaying six serum samples and two levels of LIAISON25OHVitamin
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[41] the total CVs were in the range of 12.6–10.8% (19.8–280.0 nmol/L,
7.9–112.1 ng/mL,) for serum and 9.7–9.5% (45.0–154.5 nmol/L,
18.0–61.8 ng/mL) for kit controls.
2.2.5.Isotopedilutionliquidchromatographymassspectrometry(ID-LC-MS/MS)
The serum 25(OH) D2 and 25(OH)D3 concentrations were deter-
mined by the Esoterix ID-LC-MS/MS method, which has been certiﬁed
by the CDC through the VDSCP program. The lower LoQ for the assay
was 2.5 nmol/L (1.0 ng/mL) for each 25(OH)D2 and 25(OH)D3. The
analytical measuring range was 2.5–625.0 nmol/L (1.0–250 ng/mL) for
each 25(OH)D3 and 25(OH)D2. The ID-LC-MS/MS method used in this
study measures total and fractionated vitamin D, but does not separate
the 3-epimer form of 25(OH)D [3-epi-25(OH)D].
2.3. Statistics
Correlation plots, difference plots, Bland–Altman plots, and
bias + standard deviation (SD) values were obtained using GraphPad
Prism and Microsoft Excel (2010); Analyze-It add-in program in Excel
was used to compare the different sets of data in order to obtain the
95% conﬁdence interval (CI), 95% limits of agreement, and Deming ﬁt.
3. Results
The ID-LC-MS/MS method was used to measure endogenous con-
centrations of serum 25(OH)D2, 25(OH)D3 and total 25(OH)D. At base-
line, only three subjects had detectable 25(OH)D2 [2.8, 3.2, 8.5 nmol/L
(1.1, 1.3 and 3.5 ng/mL) ]. After taking vitamin D2 supplements for
twomonths, all subjects exhibited greater than baseline concentrations
of serum 25(OH)D2.
Consistent with previous reports, 25(OH)D2 supplementation was
associated with a compensatory decrease in serum 25(OH)D3 concen-
trations (Table 1 and Fig. 1). At two months, serum 25(OH)D2 and
25(OH)D3 concentrations exhibited a 1:1 ratio and remained at their
two-month concentrations until the end of the six-month study. The
total serum 25(OH)D concentrations rose above those at baseline,
reaching equilibrium by one month (Table 1 and Fig. 1).
The total 25(OH)D concentrations measured by the ADVIA Centaur
assay and LIAISON assay, but not the ARCHITECT assay and ELECSYS
assay, were greater than baseline in subjects taking supplements for
one month. The ARCHITECT assay and ELECSYS assay results remained
at baseline concentrations throughout the study (Table 1).
The ability of the four Vitamin D Total assays to accurately measure
and monitor total serum 25(OH)D concentrations over a six-month
period compared to the ID-LC-MS/MS method was determined. The
samples containing both 25(OH)D2 and 25(OH)D3 numbered 133 out
of 140 (N2.5 nmol/L, 1 ng/mL). Regression plots and summary of the
results for total serum 25(OH)D concentrations from all subjects mea-
sured by each of the assays compared to total serum 25(OH)D concen-
trations by ID-LC-MS/MS are presented in Fig. 2. The Pearson correlation
coefﬁcients (r) were: ADVIA Centaur assay, 0.94 [95% conﬁdence inter-
val (CI) 0.91–0.95], LIAISON assay, 0.79 (CI 0.72–0.85), ELECSYS assay,
0.74 (CI 0.65–0.80), and ARCHITECT assay, 0.73 (CI 0.64–0.80) (Fig. 2).
The mean percent bias comparing each of the immunoassays to the
ID LC-MS/MS assay was similar: ADVIA Centaur assay, −7.1 + 9.3%,
ELECSYS assay, −8.4 + 18.0%; LIAISON assay, −15.3 + 14.0%; and
ARCHITECT assay, −16.3 + 14.2% (data not shown). The results for
overall average bias, overall average percent bias, along with 95% limits
of agreement plotted as a function of total serum 25(OH)D2 concentra-
tions are shown in Fig. 3.
In order to compare the bias in samples containing relatively low
25(OH)D2 concentrations (mainly those samples at baseline) with bias
in samples containing greater concentrations of 25(OH)D2, results were
analyzed by month (Table 1). The percent bias to ID-LC-MS/MS at each
of the time-points demonstrated a negative trend for the LIAISON,ELECSYS, and ARCHITECT assays, and a slight positive trend for the
ADVIA Centaur assay (Table 1, Fig. 3).
Not unexpected, the results of assay comparisons to Bland
Altman were similar to those of ID-LC-MS/MS: ADVIA Centaur assay,
−7.8 + 10% versus−7.1 + 9.3%, ELECSYS assay,−10.5 + 18.6% versus
−8.4 + 18.0%; LIAISON assay,−17.8 + 16.0% versus−15.3 + 14.0%;
and ARCHITECT assay,−19.1 + 15.9% versus−16.3 + 14.2% (data not
shown). Minimum performance requirements for the 25(OH)D assay
have been set at a mean bias of ≤ 15.8% [42]. According to this criterion,
the ADVIA Centaur assay, ELECSYS assay, and LIAISON assay results met
theminimum performance goal for comparisons to ID-LC-MS/MS results.
Three participants did not show the typical increases observed in
serum 25(OH)D2 concentrations compared to baseline (ie., they did
not achieve 25(OH)D2 values above 48.4 nmol/L (20 ng/mL)). The
serum 25(OH)D2 concentration ranges for these three participants
were as follows: Subject one, 3.2–13.3 nmol/L (1.3–5.5 ng/mL);
Subject two, 0.0–33.9 nmol/L (0.0–14 ng/mL); and Subject three,
0.0–31.5 nmol/L (0.0–13.0 ng/mL); combined range for the three
subjects: 0.0–33.9 nmol/L (0.0–14.0 ng/mL). The low serum 25(OH)D2
concentrations could have been due to a problem with absorption or
compliance. Two other subjects demonstrated gradual declines in serum
25(OH)D2 concentrations after two months [range from three to six
months: 31.5–7.3 nmol/L (13.0–3.0 ng/mL) and 50.8–13.6 nmol/L
(21.0–5.6 ng/mL)] compared to their earlier highs of 53.2 nmol/L
(22.0 ng/mL) and 67.8 nmol/L (28.0 ng/mL), respectively. Nevertheless,
all ﬁve subjects demonstrated greater than 7.3 nmol/L (3.0 ng/mL)
25(OH)D2 concentrations at each time-point after the baseline, so all sam-
ples from these subjects were included in the study [as mentioned in
Methods, ID-LC-MS/MS LoQ was 2.5 nmol/L (1 ng/mL) for 25(OH)D2].
4. Discussion
In this study we determined serum concentrations for 25(OH)D2,
25(OH)D3, and total 25(OH)D in healthy subjects receiving 2400 IU
daily vitamin D2 supplements; and, evaluated the ability of four
commercially available Vitamin D Total assays compared with the ID-
LC-MS/MS method to accurately measure and monitor total serum
25(OH)D concentrations. Optimal concentrations of total serum
25(OH)D are reported to be 75.0–110.0 nmol/L (30.0–44.0 ng/mL)
based on requirements to maintain physiological concentrations of
serum calcium, parathyroid hormone (PTH), and healthy bones [18,
43–45]. At baseline, eighty percent of subjects had total serum 25(OH)D
concentrations in the sufﬁciency range [75.0 nmol/L (30.0 ng/mL) or
greater]. The concentrations in the remaining twenty percent (four)
subjects were between 62.5 and 65.0 nmol/L (26.0–27.0 ng/mL).
Although the mean total serum 25(OH)D concentrations were
86.6 nmol/L (35.1 ng/mL), they rose on average over six months to
106.4 nmol/L (43.0 ng/mL)—a concentration reported to be safe
(non-toxic). (The safe range has been reported to be b220.0 nmol/L
(b88.0 ng/mL) [15,18].) The 20.0 nmol/L (8.0 ng/mL) mean increment
is similar to the 15.0–17.5 nmol/L (6.0-7.0 ng/mL) increase in circulat-
ing 25(OH)D generally found for 1000 IU daily vitamin D3 dosing [12,
16,46]. Heaney et al. [12] showed that healthy subjects [with a basal
total serum 25(OH)D concentrations of 72 nmol/L (28.8 ng/mL) and
65.6 nmol/L (26.24 ng/mL) who were receiving 25.0 and 250.0 μg
(1000 to 10,000 IU) daily vitamin D3] could increase their total
25(OH)D concentrations by 12.0 and 158 nmol/L (4.8 and 63.4 ng/mL)
after ﬁve months, respectively. Thus, it is possible that higher than a
2400 IU daily dose of vitamin D2 could have led to greater total serum
25(OH)D concentrations in these healthy individuals. The continuous
daily dosing time-to-equilibrium for total serum 25(OH)D concentra-
tions was about one month—faster than the ﬁve months reported for a
1000 IU daily dose of 25(OH)D3 [12].
We do not know if 2,400 IU daily of vitamin D2 would increase
25(OH)D concentrations in vitamin D deﬁcient adults (b50.0 nmol/L, b
20.0 ng/mL,) into the optimal range; this was not a goal of the study.
Table 1
Statistics for serum concentrations of total 25(OH)D, 25(OH)D2 and 25(OH)D3 as determined by ID-LC-MS/MS, ADVIA Centaur (Centaur), LIAISON, ELECSYS, and ARCHITECT assays.
Analyte, Mean (+SD) Median nmol/L Interquartile (IQ) range nmol/L Minimum nmol/L Maximum nmol/L Percent bias to
ID-LC-MS/MS (+SD)
Baseline,
0 h
ID-LC-MS/MS 86.61 (15.09) 86.35 76.70–99.38 62.50 112.50
D Total 0.83 (2.06) 0 00.00–00.00 00.00 8.47
D2 84.03 (16.46) 85.00 66.88–95.63 55.00 112.50
D3 74.64 (12.97) 73.95 64.78–85.43 51.70 99.40 −13.4 (8.2)
Centaur 83.23 (17.22) 82.15 72.18–90.50 52.70 116.30 −3.5 (14.6)
LIAISON 95.95 (31.03) 88.20 76.00–105.20 62.80 189.00 9.6 (21.2)
ELECSYS ARCHITECT 86.47 (21.08) 88.00 68.30–93.60 57.40 154.50 −0.2 (15.3)
1 month ID-LC-MS/MS
D Total 107.00 (18.32) 108.80 91.27–122.50 65.60 140.60
D2 43.55 (15.09) 44.77 36.30–53.24 5.57 67.76
D3 63.44 (16.27) 62.50 52.50–74.38 23.75 87.50
Centaur 101.40 (19.36) 98.60 88.78–117.00 63.80 145.50 −5.1 (7.5)
LIAISON 97.19 (23.55) 102.6 80.98–107.80 59.40 160.10 −9.6 (12.1)
ELECSYS 97.17 (28.13) 91.70 81.70–108.50 62.30 176.10 −9.0 (17)
ARCHITECT 87.58 (19.56) 88.20 69.30–102.30 58.60 138.00 −16.7 (11.6)
2 months ID-LC-MS/MS
D Total 106.60 (20.39) 105.70 88.88–124.90 73.30 150.00
D2 54.81 (18.10) 55.66 51.43–64.74 13.31 84.70
D3 51.75 (15.86) 55.00 37.50–64.38 22.50 75.00
Centaur 98.69 (24.37) 90.45 78.83–121.00 55.90 138.80 −8.2 (8.7)
LIAISON 87.18 (23.74) 88.45 65.33–102.30 58.70 133.10 −18.7 (12.6)
ELECSYS 94.02 (29.84) 88.75 73.15–103.50 48.20 180.60 −12.6 (15.8)
ARCHITECT 85.81 (19.83) 83.15 70.43–99.05 57.80 138.40 −19.1 (12.9)
3 months ID-LC-MS/MS
D Total 111.70 (25.11) 106.9 96.27–128.50 78.30 167.30
D2 53.47 (18.60) 58.08 47.19–67.76 9.44 82.28
D3 58.25 (19.79) 60.00 40.00–71.88 27.50 97.50
Centaur 105.00 (25.56) 97.60 90.03–120.90 72.20 157.20 −6.1 (6.9)
LIAISON 87.91 (25.12) 82.20 68.33–111.30 54.10 152.20 −21.5 (12.5)
ELECSYS 96.96 (30.42) 95.20 72.45–116.20 57.80 185.40 −13.6 (15.1)
ARCHITECT 86.16 (20.30) 81.70 73.23–99.05 52.10 133.80 −22.5 (10.6)
4 months ID-LC-MS/MS
D Total 110.90 (24.09) 108.30 90.95–129.10 69.10 165.20
D2 51.62 (19.19) 58.08 31.46–67.76 17.42 79.86
D3 59.25 (15.07) 58.75 48.13–69.38 30.00 95.00
Centaur 105.30 (27.98) 104.20 84.08–129.80 58.10 155.90 −5.8 (9.3)
LIAISON 88.94 (24.15) 81.40 71.85–107.10 58.30 146.30 −20.1 (10.3)
ELECSYS 101.90 (31.11) 92.70 84.23–120.10 64.20 206.50 −8.3 (15.1)
ARCHITECT 90.29 (20.11) 92.00 72.48–105.50 58.30 133.00 −18.1 (9.4)
5 months ID-LC-MS/MS
D Total 109.3 (27.01) 106.7 89.00–124.4 61.20 159.90
D2 54.55 (24.89) 59.29 35.70–74.41 11.86 91.96
D3 54.78 (14.38) 55.00 45.00–65.00 23.00 80.00
Centaur 104.00 (29.90) 93.90 86.18–118.40 55.20 170.40 −5.3 (9.2)
LIAISON 93.69 (26.19) 86.65 75.80–106.40 62.00 165.20 −13.6 (14.0)
ELECSYS 94.84 (30.40) 87.20 74.55–114.7 49.60 187.00 −13.1 (16.2)
ARCHITECT 86.62 (23.45) 84.10 68.38–92.43 58.00 142.80 −19.8 (14.2)
6 months ID-LC-MS/MS
D Total 106.40 (24.09) 100.3 91.25–121.80 66.10 159.70
D2 51.63 (26.73) 56.87 26.80–73.21 7.26 96.80
D3 54.75 (15.6) 50.00 42.50–70.00 25.00 85.00
Centaur 102.00 (32.74) 92.70 77.10–125.8 52.70 167.30 −5.7 (12.7)
LIAISON 85.95 (28.97) 79.90 63.45–105.8 44.10 157.50 −20.3 (13.3)
ELECSYS 93.93 (30.42) 86.70 74.28–105.30 56.30 189.20 −12.1 (15.1)
ARCHITECT 86.70 (21.19) 85.75 67.65–97.23 58.00 126.7 −17.8 (14.0)
The number of subjects at eachmonthly measurement was 20, except at one month when the number of subjects for ELECSYS and ARCHITECT was 19 each. Total nmole/L for each assay
was calculated using the ID-LC-MS/MS 25(OH)D2/25(OH)D3 ratio as described in Methods. To convert 25(OH)D concentrations to nanograms per milliliter (ng/mL), divide by 2.5 for
25(OH)D3 and 2.42 for 25(OH)D2. Interquartile (IQ) Range: Values ranging from the 25th to the 75th percentile.
1100 J. Freeman et al. / Clinical Biochemistry 48 (2015) 1097–1104However, we surmise that 2,400 IU daily may not be sufﬁcient based on
the results of several studies—albeit those studies used different regimens
of vitaminD2 or vitaminD3 [13,46]—and theEndocrine Society guidelines
that recommend initial treatment of vitamin D deﬁcient adults with
vitamin D2 or vitamin D3 doses of 50,000 IU once a week or 6000 IU per
day to achieve a blood concentration of 25(OH)D above 30.0 ng/mL [2].
In the present study, 2400 IU daily of vitamin D2 led to higher serum
25(OH)D2 concentrations and lower serum 25(OH)D3 concentrations
than baseline; total serum 25(OH)D concentrations were higher than
baseline. These compensatory ﬁndings are consistent with the results
of others; [8,10,23,27] whereas, total serum 25(OH)D concentrations
were reported to be higher [8], lower [23], or unchanged in thosestudies [13,27]—likely a reﬂection of the study design, dosing regimen
and baseline serum 25(OH)D concentrations, as mentioned earlier. A
similar reciprocal compensatory response was reported after vitamin D3
supplementation, (i.e., rise in serum 25(OH)D3 and decline in serum
25(OH)D2 concentrations). Both vitamin D2- and vitamin D3-induced
compensatory responses likely involve similar feedback mechanisms or
competition for common metabolic pathways [8,47].
Vitamin D2 metabolites appear to be less effective at increasing
serum 25(OH)D concentrations, especially when given as a bolus dose
compared with daily dosing [8,10,20–26,48,49]. The present study did
not directly compare the efﬁcacy of vitamin D2 and vitamin D3, so we
do not know whether a similar daily dose of 25(OH)D3 would have
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25(OH)D2. This study demonstrated that 2400 IU daily led to a mean
increment in 25(OH)D of 20.0 nmol/L (8.0 ng/mL); this is more than
two fold the amount of vitamin D3 reported to raise 25(OH)D by the
same amount (ie., 1000 IU daily of vitamin D3 raised total serum
25(OH)D concentrations by about 15.0–17.5 nmol/L (6.0–7.0 ng/mL))
[12,16,46]. Although indirect, these assumptions support reports that
25(OH)D3 supplementation is at least 30–50% more effective than
25(OH)D2 in maintaining total serum 25(OH)D concentrations [8,10,
20–26,48,49].
Variability for automated and other methods in the measurement
of 25(OH)D has been attributed to a variety of sources including dif-
ferential recognition of 25(OH)D3 and 25(OH)D2 by the capture an-
tibody [29–32], and 25(OH)D is a difﬁcult analyte to measure due to
its hydrophobic properties and tight binding to an abundance of
serum binding proteins. Additionally, due to its lower afﬁnity for bind-
ing proteins, 25(OH)D2 in serummay be preferentially released andmore25(OH)D Total (nmol/L)
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Fig. 3.Difference plots demonstrating bias and percent bias to ID-LC-MS/MS versus serum 25(OH)D2 concentrations. A. and B.: ADVIA Centaur; C. and D.: LIAISON; E. and F.: ELECSYS; G. and H:
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the case for theADVIACentaur assaywhich showed a slight positive trend
for bias compared to ID-LC-MS/MS serum 25(OH)D2 concentrations in-
creased. This is consistent with the product labeling [104.5% cross-
reactivity with 25(OH)D2 and 100.7% cross-reactivity with 25(OH)D3].
Compared with the ADVIA Centaur assay that was used in previous stud-
ies, the assay in the present study was calibrated with new standard
values and is traceable to the Ghent University 25(OH)vitamin D RMP.
A recent studydemonstrated acceptable bias for individualswithdifferent
concentrations of vitamin D binding protein and 25(OH)-D2 concentra-
tions using this assay [51]. The Esoterix ID-LC-MS/MS method used in
the present study detects 3-epi-25(OH)D2 or 3-epi-25(OH)D3 as part of25(OH)D2 and 25(OH)D3, so the ID-LC-MS/MS method may have
overestimated 25(OH)D values.
Limitations of the study include the following: First, none of the
subjects had total serum 25(OH)D concentrations lower than 48 nmol/L
(20.0 ng/mL), so bias and clinical concordance at the medical decision
point could not be assessed; however, the ADVIA Centaur assay and
ELECSYS assay results for bias to ID-LC-MS/MS for subjects with
25(OH)D2 ranging from 0.0 to 48.0 nmol/L were acceptable when com-
pared to the bias for subjects with total 25(OH)D or 25(OH)D2 concen-
trations over 48.0 nmol/L (Fig. 3 and Table 1). Second, no placebo
groupwas included in the study to control for changes in serum concen-
trations of 25(OH)D2 and 25(OH)D3 over time. It is unlikely that the
1103J. Freeman et al. / Clinical Biochemistry 48 (2015) 1097–1104subjects' diets would have changed such that serum 25(OH)D2 and total
serum 25(OH)D concentrations would rise as quickly as they did within
the ﬁrst fewweeks concomitantwith a decline in 25(OH)D3 serum con-
centrations. In addition, samples were collected in spring/early summer
making it unlikely that vitamin D3 concentrations would decline due to
lack of exposure to sunlight. Third, serum PTH and calcium concentra-
tions were not measured. Serum 25(OH)D concentrations regulate
physiological concentrations of serum PTH [12,45]. The highest total
serum 25(OH)D concentration measured in this study by ID-LC-MS/MS
was 167.3 nmol/L (68 ng/mL) which was reported to be within the
safe range for maintaining serum PTH and calcium concentrations
(b220.0 nmol/L, b88.0 ng/mL) [16,18]. Future studies will include
serum PTH and calcium measurements. The strengths of the study
include adequate number of samples representative of apparently
healthy subjects receiving vitamin D2 (D2:D3 ratio of 1:1); relatively
long study (6 months); good participant compliance with protocol;
use of a comparison VDSCP-certiﬁed ID-LC-MS/MS method traceable
to NIST; use of at least one assay, ADVIA Centaur Vitamin D Total
assay, traceable to the Ghent University 25(OH)vitamin D RMP that
has also achieved certiﬁcation by the CDC VDSCP.
5. Conclusions
The 25(OH)D bias results for the ADVIA Centaur assay and ELECSYS
assay were slightly lower than those for the LIAISON assay and the
ARCHITECT assay; however, this study demonstrated that all 25(OH)D
assays achieved acceptable performance.
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